Thymoquinone Induces Human Platelet Aggregation via Cytochrome P450 and Mitochondria

N. B. AMOR

Department of Public Health, Veterinary College, King Faisal University, Al Hofuf 31982, Saudi Arabia, *Department of Biotechnology, Higher Institute of Biotechnology of Beja, University of Jendouba, Beja, Jendouba 8189, Tunisia

Amor: Thymoquinone Induces Human Platelet Aggregation

Platelets are small circulating anucleated cells, resulting from the fragmentation of megakaryocytes. They are directly involved in primary hemostasis, where they are among the first elements to intervene in stopping bleeding. Platelet count or functional alteration was reported to be correlated to different types of diseases. Since antiquity, plants have been used to cure panoply of diseases. *Nigella sativa*, black cumin, is an annual Mediterranean plant. *Nigella sativa*’s main essential oil constituent, thymoquinone (30 %–48 %) is responsible for a number of its biological activity. Various drugs and plant substances can induce thrombocytopenia. Some studies describe a dose and time-dependent decrease of platelet count induced by consumption of these substances. Thymoquinone is a quinine-like compound; quinines are involved in drug-induced immune thrombocytopenia. Indeed, human consumption and rat administration of black seed oil for 4 and 12 w, respectively, induce thrombocytopenia. To date, the thymoquinone effect on platelets is not fully understood. Here we bring new elements on the effects of thymoquinone on platelet aggregation. Our results show that thymoquinone by itself is able to induce platelet aggregation, but needs a relatively long exposure (28 min). We also show that thymoquinone-induced platelet aggregation is probably mediated through cytochrome metabolites but mainly via the mitochondrial pathway. Results demonstrate that platelets pre-incubation with thymoquinone abrogate thrombin-induced platelet aggregation in a concentration-dependent manner.

In conclusion, black seeds and thymoquinone consumption as nutritional complement or as alternative medicine should be in low concentration and under phyto-specialists or medical supervision.

Key words: Thymoquinone, platelet aggregation, cytochrome P450, mitochondria

Blood platelets are small circulating anucleated cells, resulting from the fragmentation of their hematopoietic precursor, resident in the marrowbone, the megakaryocyte. Platelets are directly involved in primary hemostasis, where they will be among the first elements to intervene in stopping bleeding. They will locally undergo various changes related to their hemostatic activity. Platelet aggregation might be either reversible or irreversible. The reversible aggregation will take place as a mission that the repair of the small damages that take place in the subendothelium and vascular tissue, while the phenomenon of irreversible aggregation will take place when the damage is very serious and the formation of a platelet thrombus is required[1]. Platelet count or functional alteration is associated to a number of diseases[2-4]. Thrombocytopenia is the decrease of platelet count to less than 150 000/ml and caused by platelet production decrease or high consumption and sequestration. Various drugs and plant substances can induce thrombocytopenia. Some studies report 25 non-quinine substances from foods, beverage, herbal and nutritional supplements rather than medicines are associated to thrombocytopenia[5]. They also describe a dose and time-dependent decrease of platelet count induced by these substances[6].

Since ancient times, plants have been used to cure a plethora of disorders. *Nigella sativa* (*N. sativa*), black cumin is an annual Mediterranean plant. Its oil was used in Arabic medicine to heal arthritis, lung disease and hypercholesterolemia[7]. Studies have shown that the biological activity of *N. sativa* seeds is mainly due to its essential oil, mainly composed of Thymoquinone (TQ) (30 %–48 %)[8].

The therapeutic potential of TQ has attracted the attention of a number of research groups to characterize its molecular mechanism. Indeed many scientists underline TQ high scavenging proprieties of superoxide...
and free radicals. This ability gives TQ the ability to modulate cellular antioxidant defense enzymes. Moreover, several studies attribute to TQ the capability to inhibit tumor cell proliferation via several signaling pathways.

TQ does not only have beneficial virtues. TQ is quinine like compound and quinines are involved in drug-induced immune thrombocytopenia. Thus, TQ might act through the same mechanism that induces thrombocytopenia. Indeed, oral administration of *N. sativa* fixed oil in mice and rats during 12 w causes 15 % to 35 % decrease in platelet count. In humans, consumption of black seed oil for 1 mo has been reported to induce thrombocytopenia. TQ poses an apoptotic effect on platelets mediated by G protein-coupled receptors that may explain platelet count decrease. Until now, the effect of TQ on platelets has not been fully understood. Here we shed new light on the effect of TQ on platelet aggregation. We demonstrate for the first time that TQ by itself is capable to stimulate platelet aggregation and abrogates the effect of thrombin.

**MATERIALS AND METHODS**

**Materials:**

Apyrase (grade VII), Ethylene Glycol Tetraacetic Acid (EGTA) AQ1, aspirin, Bovine Serum Albumin (BSA), thrombin, TQ, rotenone and oligomycin A were from Sigma (Madrid, Spain). Calcein was from Molecular Probes (Leiden, The Netherlands). All other reagents were purchased from Panreac (Barcelona, Spain). The thrombin preparation (specific activity P2000 National Institute of Health (NIH) units/mg protein) was predominantly Alpha (α) thrombin, containing minimum autolytic digestion products, according to the manufacturer’s instructions. Therefore, most of the effects shown in the present study should be attributed to α-thrombin.

**Platelet preparation:**

Blood was obtained from healthy volunteers, according to the rules of the Declaration of Helsinki and mixed with one-sixth volume of acid/citrate dextrose anticoagulant containing (in mM): 85 sodium citrate, 78 citric acid and 111 D-glucose. Platelet-rich plasma was then prepared by centrifugation for 5 min at 700 g and apyrase (40 µg/ml) added. Cells were then collected by centrifugation at 350 g for 20 min and resuspended in HEPES-Buffered Saline (HBS) containing (in mM): 145 Sodium chloride (NaCl), 10 HEPES, 10 D-glucose, 5 Potassium chloride (KCl), 1 Magnesium sulfate (MgSO₄), pH 7.45 and supplemented with 0.1 % w/v BSA and 40 µg/ml apyrase.

**Cell viability:**

Cell viability was assessed using calcein and trypan blue. For calcein loading, cells were incubated for 30 min with 5 µM Calcein-Acetoxyethyl Ester (calcein-AM) at 37 °C. Resting platelets in suspension are arbitrarily considered by the aggregometer as 0 % aggregation and HBS is considered to be 100 % aggregation. The rate or slope of the aggregation is the percentage change of aggregation per minute.

**Statistical analysis:**

Analysis of statistical significance was performed using Student’s t test where p<0.05 was considered to be significant for a difference.

**RESULTS AND DISCUSSION**

*N. sativa* is widely consumed in Mediterranean, Middle East and Asian countries, for its beneficial effects. TQ, the main biological active compound of *N. sativa*, has the capacity to reduce oxidative stress and induce apoptosis in many types of cancer. The effect of TQ in platelet physiology is controversial and a number of studies associate TQ to thrombocytopenia, induction of platelets apoptosis or no effect on platelet aggregation.
To explore the effect of TQ on human platelet aggregation, we incubated cells with 0.5, 1, 5 and 10 µM of TQ at 37° and 1200 rpm stirring. We noticed that, all the concentrations of TQ used, caused platelet aggregation with the same amplitude as 0.1 U/ml of thrombin (fig. 1 and Table 1, no significant values comparing to 0.1 U/ml of thrombin; n=10). Interestingly, the lag-time for TQ-induced platelet aggregation was very long, about 28 min for 5 and 10 µM without affecting the slope compared to 0.1 U/ml thrombin (Table 1). TQ, 1 and 0.5 µM are also able to induce slow platelet aggregation, (lag-time was 2130±276 and 1229±607 s, respectively) with a smaller slope (40.5±4.33 and 47.66±2.84, respectively) (Table 1).

Arachidonic acid metabolites are one of the main platelet aggregation pathways. To investigate the role of Cytochrome P450 (CYP-450) in TQ-induced platelet aggregation, we preincubated platelets with 10 µM of 17-Octadecynoic acid (17-ODYA), a CYP-450 inhibitor for 10 min. Treatment with 17-ODYA attenuated TQ-induced aggregation by 15 % for 0.5 and 1 µM TQ and 10 % for 5 µM TQ. 17-ODYA seems no effect on aggregation amplitude when 10 µM of TQ was used (fig. 2 and Table 2). We noticed that 17-ODYA also reduces the lag-time of TQ-induced platelet aggregation (Table 2).

Towhid and coworkers reported a mitochondrial membrane depolarization in TQ-induced platelet apoptosis[18]. To assess the contribution of mitochondria in TQ-induced platelet aggregation, we incubated platelets for 10 min with 10 µM rotenone, an electron transport chain Complex I inhibitor and 10 µM oligomycin A, an inhibitor of Adenosine Triphosphate (ATP) synthase (used to avoid ATP depletion), prior to platelet stimulation with 5 and 10 µM of TQ. Treatment with oligomycin A and rotenone resulted in attenuation of the amplitude of platelet aggregation and increase in the lag-time (fig. 3 and Table 2), thus suggesting that mitochondria plays a relevant role in platelet aggregation induced by TQ.

![Fig. 1: TQ induces platelets aggregation](image-url)

**Note:** Human platelets were suspended in a HBS containing 1 mM Ca$^{2+}$ and then were incubated in 0.5, 1, 5 and 10 µM of TQ or with 0.1 U/ml thrombin. Platelet aggregation was induced as described. Values given are presented as mean±Standard Error of the Mean (SEM) of six separate determinations. No significant values are recorded

**TABLE 1: TQ EFFECT ON PLATELETS AGGREGATION**

<table>
<thead>
<tr>
<th>Stimulus</th>
<th>Amplitude</th>
<th>Slope</th>
<th>Lag-time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thrombin 0.1 U</td>
<td>78.7±1.8</td>
<td>65.2±2.9</td>
<td>35.8±4.9</td>
</tr>
<tr>
<td>TQ 10 µM</td>
<td>76.4±2.2</td>
<td>65.0±2.8</td>
<td>1707.0±35.6**</td>
</tr>
<tr>
<td>TQ 5 µM</td>
<td>78.5±1.1</td>
<td>64.4±4.6</td>
<td>1596.0±84.5**</td>
</tr>
<tr>
<td>TQ 1 µM</td>
<td>79.5±1.9</td>
<td>40.5±4.3*</td>
<td>2130.0±276.1**</td>
</tr>
<tr>
<td>TQ 0.5 µM</td>
<td>77.3±1.6</td>
<td>47.6±2.8*</td>
<td>1229.0±607.0**</td>
</tr>
</tbody>
</table>

**Note:** Values given are presented as mean±SEM of six separate determinations; *p<0.05, **p<0.001 compared to thrombin-induced response in the absence of agents
Fig. 2: Effect of 17-ODYA on TQ induced platelet aggregation. Values given are presented as mean±SEM of six separate determinations; *p<0.05 compared to TQ-induced response

TABLE 2: TQ INDUCES PLATELET AGGREGATION via CYP AND MITOCHONDRIAL PATHWAY

<table>
<thead>
<tr>
<th>Agent</th>
<th>Stimulus</th>
<th>Amplitude</th>
<th>Slope</th>
<th>Lag-time (s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thrombin</td>
<td></td>
<td>78.7±1.8</td>
<td>65.2±2.9</td>
<td>35.8±4.9</td>
</tr>
<tr>
<td>17-ODYA</td>
<td>TQ 10 µM</td>
<td>74.8±2.0</td>
<td>51.5±4.3*</td>
<td>1439.0±73.9**†</td>
</tr>
<tr>
<td>17-ODYA</td>
<td>TQ 5 µM</td>
<td>71.4±1.2*†</td>
<td>49.2±4.2*</td>
<td>1362.0±54.5**†</td>
</tr>
<tr>
<td>17-ODYA</td>
<td>TQ 1 µM</td>
<td>68.0±2.6*†</td>
<td>43.6±2.5**</td>
<td>1004.6±184.1***†</td>
</tr>
<tr>
<td>17-ODYA</td>
<td>TQ 0.5 µM</td>
<td>65.2±2.1*†</td>
<td>51.0±3.7*</td>
<td>625.1±60.3**†</td>
</tr>
<tr>
<td>Rot+Oligo</td>
<td>TQ 10 µM</td>
<td>62.7±0.4*†</td>
<td>77.2±5.4*†</td>
<td>1592.2±32.2**†</td>
</tr>
<tr>
<td>Rot+Oligo</td>
<td>TQ 5 µM</td>
<td>67.0±1.5*†</td>
<td>72.5±10.1</td>
<td>1266.0±33.0**†</td>
</tr>
</tbody>
</table>

Note: Values given are presented as mean±SEM of four to six separate determinations; *p<0.05, **p<0.01 compared to thrombin-induced response in the absence of agents; †p<0.05 compared to TQ-induced response

Fig. 3: Rotenone and oligomycin impairs TQ-induced platelet aggregation. Values given are presented as mean±SEM of four separate determinations; *p<0.05 compared to TQ-induced response
Thrombin is a strong platelet physiological agonist that induces cytosolic calcium mobilization, cytoskeletal reorganization, granule secretion, changes in cell shape and aggregation. In order to investigate the role of TQ on thrombin-evoked platelet aggregation, platelets were pretreated with different concentration (0.5, 1, 5 and 10 µM) of TQ at 37° for 15 min under stirring conditions (1200 rpm) and then stimulated with 0.1 U/ml thrombin. As shown in fig. 4 and Table 3, TQ significantly decreased the aggregation amplitude and the slope of thrombin-induced platelet aggregation but without effect on the lag-time. The maximum effect was recorded with 10 µM TQ with a 38±3 % inhibition in the amplitude and 38±1 % in the slope (p<0.05; N=6).

As shown in fig. 5 and Table 4, platelet treatment with 0.5, 1, 5 and 10 µM of TQ at 37° for 15 min in combination with 10 µM of 17-ODYA for 10 min significantly reduced thrombin-induced aggregation as compared to their respective controls. The aggregation amplitude and the slope were decreased and the lag-time was enhanced. When platelets were treated with TQ in combination with 17-ODYA, the inhibitory effect on thrombin-induced aggregation was greater than that observed with TQ alone (fig. 5 and Table 4; p<0.05 n=4).

The effect of TQ on platelet physiology remains controversial, indeed, some studies report that only high doses of TQ (20-100 µg/ml) inhibit collagen and Adenosine Diphosphate (ADP) induced platelet aggregation in rats[20] and some others describe no effect on platelet aggregation[20-22].

![Fig. 4: Effect of TQ on thrombin-induced platelet aggregation. Values given are presented as mean±SEM of four to six separate determinations; *p<0.05, **p<0.01 compared to thrombin-induced response in the absence of agents](image)

**TABLE 3: TQ EFFECT ON THROMBIN INDUCED PLATELETS AGGREGATION**

<table>
<thead>
<tr>
<th>Agent</th>
<th>Stimulus</th>
<th>Amplitude</th>
<th>Slope</th>
<th>Lag-time (s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thrombin</td>
<td>Thrombin</td>
<td>78.7±1.8</td>
<td>65.2±2.9</td>
<td>35.8±4.9</td>
</tr>
<tr>
<td>TQ 10 µM</td>
<td>Thrombin</td>
<td>48.3±2.8**</td>
<td>38.0±1.0**</td>
<td>39.5±0.3</td>
</tr>
<tr>
<td>TQ 5 µM</td>
<td>Thrombin</td>
<td>67.0±1.0*</td>
<td>53.3±6.5*</td>
<td>33.0±5.0</td>
</tr>
<tr>
<td>TQ 1 µM</td>
<td>Thrombin</td>
<td>74.0±2.0*</td>
<td>48.6±6.9*</td>
<td>42.5±1.5</td>
</tr>
<tr>
<td>TQ 0.5 µM</td>
<td>Thrombin</td>
<td>71.0±2.0*</td>
<td>59.0±2.0*</td>
<td>45.0±13.0</td>
</tr>
</tbody>
</table>

Note: Values given are presented as mean±SEM of four to six separate determinations; *p<0.05, **p<0.01 compared to thrombin-induced response in the absence of agents

![Fig. 5: Effect of TQ in combination with 17-ODYA on thrombin-induced platelet aggregation. Values given are presented as mean±SEM of four separate determinations; *p<0.05, **p<0.01 compared to thrombin-induced response in the absence of agents †p<0.05 compared to thrombin-induced response in the presence of TQ](image)
To investigate the effect of TQ on human platelet aggregation, we incubated cells with increasing concentrations of TQ (0.5, 1, 5 and 10 µM). Our results showed for the first time that all TQ concentrations used enhanced platelet aggregation with similar amplitude as 0.1 U/ml of thrombin. Interestingly, TQ-induced platelet aggregation shows a significantly longer lag-time than stimulation with thrombin. No previous studies report that TQ is able to induce platelet aggregation in contrast they describe that platelet incubation with TQ was without effect[22]. This can be explained by the short time of TQ incubation (3 min). Our lag-time for platelet aggregation is in agreement with the study by Towhid et al.[18] reporting that 10 µM of TQ activates Phosphoinositide 3-kinases (PI3K), caspase 3 and increase in cytosolic calcium concentration, so platelet activation, after 30 min of TQ incubation.

Mitochondria play an important role in platelet functionality via ATP synthesis, redox state modulation and caspase activation[23,24]. By uncoupling mitochondria with rotenone in the presence of oligomycin A, we have found that mitochondria play a relevant role in TQ-induced human platelet. These findings are in accordance with a previous study describing that inhibition of mitochondria electron transport chain or oxidative phosphorylation reverse the effect of hyperglycemia on Reactive Oxygen Species (ROS) generation, suggesting a mitochondrial role. In addition, mitochondria can produce superoxide, responsible of platelets dysfunction in diabetic patients[25].

It was previously reported that TQ-induced apoptosis in chondrocytes and ovarian cancer cells via ROS generation and may participate in membrane electron-transport chains between complex I and complex III leading to superoxide anion and hydroxyl radical production[26-28]. We have further found that arachidonic acid metabolism might also play a role in the mechanism underlying platelet aggregation upon stimulation with TQ, as demonstrated by the inhibitory effect of treatment with 17-ODYA, which prevents the metabolism of arachidonic acid by CYP-450, on TQ-evoked response; thus suggesting a possible role for CYP-450-dependent arachidonic acid metabolites in TQ-induced platelet aggregation, as previously suggested[29].

Next, we have explored the possible role of TQ on agonist-induced platelet aggregation. Our results indicate that treatment with TQ significantly decrease thrombin-induced platelet aggregation. This is in consistent with previous study describing that platelet pretreatment with 40 µM TQ for 60 min inhibit thrombin induced aggregation. Another study proposed that TQ possesses anticoagulant effect and inhibits cancer cell-induced coagulation[22].

TQ has a very similar structure to Tert-Butylhydroquinone (TBHQ), a synthetic reduced quinone[30]. We have previously shown that acidic store depletion by 20 µM TBHQ, a Sarco/Endoplasmic Reticulum (SERCA) Calcium (Ca²⁺)-ATPase (SERCA)-3 selective inhibitor impairs thrombin-induced platelet aggregation[31]. Although speculative, TQ might mimic the effect of TBHQ on thrombin-induced aggregation.

Our results show that when platelets were treated with TQ in combination with 17-ODYA, the inhibitory effect was greater than that observed with TQ alone.

It was reported that TQ downregulates cyclooxygenases, 5-lypooxygenases, inhibit thromboxane B2, prostaglandin and leukotriene B4 metabolites formation[32]. In addition, TQ has the ability to inhibit CYP-450 enzymatic function and decrease the enzyme level[33]. Thus, we suggest that TQ

<table>
<thead>
<tr>
<th>Agent</th>
<th>Stimulus</th>
<th>Amplitude</th>
<th>Slope</th>
<th>Lag-time (s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TQ 10 µM</td>
<td>Thrombin</td>
<td>78.7±1.8</td>
<td>65.2±2.9</td>
<td>35.8±4.9</td>
</tr>
<tr>
<td>TQ 10 µM</td>
<td>Thrombin</td>
<td>76.3±2.2</td>
<td>66.3±4.7</td>
<td>1707.0±35.6**</td>
</tr>
<tr>
<td>TQ 10 µM+17-ODYA</td>
<td>Thrombin</td>
<td>48.3±2.8**</td>
<td>38.0±1.0**</td>
<td>39.5±0.3</td>
</tr>
<tr>
<td>TQ 5 µM+17-ODYA</td>
<td>Thrombin</td>
<td>46.0±1.0**</td>
<td>37.0±0.5**</td>
<td>42.0±6.0</td>
</tr>
<tr>
<td>TQ 1 µM+17-ODYA</td>
<td>Thrombin</td>
<td>50.5±3.5**</td>
<td>46.0±7.0*</td>
<td>54.0±1.0*</td>
</tr>
<tr>
<td>TQ 0.5 µM+17-ODYA</td>
<td>Thrombin</td>
<td>68.5±0.4*</td>
<td>44.3±3.1**</td>
<td>43.0±1.7**</td>
</tr>
</tbody>
</table>

Note: Values given are presented as mean±SEM of four separate determinations; *p<0.05, **p<0.01 compared to thrombin-induced response in the absence of agents.
might impair thrombin-induced platelet aggregation through: Inhibition of arachidonic acid metabolism, indeed Enamoto et al. describes such inhibition by N. sativa methanol extract.[34] In our previous work we demonstrate that the selective depletion of the dense tubular system leads to 5,6-Epoxycosatrienoic acid (5,6-EET) production and activation of Store-Operated Ca\(^{2+}\) Entry (SOCE), which was impaired by 17-ODYA, we have also noticed that 5,6 EET-induces Ca\(^{2+}\) entry needs a redox state maintained by a basal level of H\(_2\)O\(_2\).[35]; decreasing cytosolic Ca\(^{2+}\) concentration via SOCE inhibition and impairment of ROS production necessary to maintain a minimum redox state required for platelet physiological response.

Summarizing, TQ in the low micromolar range is able to induce human platelet aggregation after 25-28 min of incubation by a mechanism that requires functional mitochondria and CYP-450. In addition, TQ is able to attenuate thrombin-evoked platelet aggregation in a concentration-dependent manner.

**Acknowledgements:**

The author extends his appreciation to the Deanship of Scientific Research, Vice Presidency for Graduate Studies and Scientific Research, King Faisal University, Saudi Arabia, for funding this research work through grant number 1794. The author acknowledges Dr. Juan Antonio Rosado and the Cell Physiology Research Group, Veterinary College, University of Extremadura, Spain.

**Conflict of interests:**

The authors declared no conflict of interest.

**REFERENCES**


